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O B J E C T I V E S This study sought to evaluate whether impaired vasodilator function, an early
manifestation of coronary artery disease, which precedes angiographic stenosis, accounts for increased
risk among patients with moderate to severe renal dysfunction.
B A C KG ROUND Patients with renal dysfunction are at increased risk of adverse cardiac outcomes,
even in the absence of overt myocardial ischemia or infarction.
METHOD S We included 866 consecutive patients with moderate to severe renal dysfunction referred
for rest and stress myocardial perfusion positron emission tomography and followed them for a median of
1.28 years (interquartile range: 0.64 to 2.34). Regional myocardial perfusion abnormalities were assessed by
semiquantitative visual analysis of positron emission tomography images. Rest and stress myocardial blood
ﬂow were calculated using factor analysis and a 2-compartment kinetic model; they were also used to
compute coronary ﬂow reserve (stress/rest myocardial blood ﬂow). The primary endpoint was cardiac death.
R E S U L T S Overall, 3-year cardiac mortality was 16.2%. After adjusting for clinical risk, left ventricular
ejection fraction, as well as the magnitude of scar and/or ischemia, coronary ﬂow reserve below the median
(1.5) was associated with a 2.1-fold increase in the risk of cardiac death (95% conﬁdence interval [CI]: 1.3
to 3.5, p 0.004). Incorporation of coronary ﬂow reserve into cardiac death risk assessment models resulted
in an increase in the C-index from 0.75 to 0.77 (p  0.05) and in a net reclassiﬁcation improvement of 0.142
(95% CI: 0.076 to 0.219). Among patients at intermediate risk based on all data other than coronary ﬂow
reserve, the net reclassiﬁcation improvement was 0.489 (95% CI: 0.192 to 0.836). Corresponding improve-
ments in risk assessment for mortality from any cause were also demonstrated.
CONC L U S I O N S The presence of coronary vascular dysfunction in patients with moderate to
severe renal dysfunction, as assessed by positron emission tomography, is a powerful, independent
predictor of cardiac mortality and provides meaningful incremental risk stratiﬁcation over conventional
markers of clinical risk. (J Am Coll Cardiol Img 2012;5:1025–34) © 2012 by the American College of
Cardiology Foundation
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1026ardiovascular disease is the leading cause
of mortality among patients with moder-
ate to severe renal dysfunction (1). In
selected high-risk patients, early referral to
ardiac catheterization and coronary revasculariza-
ion may improve outcomes (2). However, acute
eterioration of renal function following diagnostic
oronary angiography occurs in approximately 10%
f patients (3) and up to 30% of patients after
ercutaneous coronary intervention (4). Contrast
edium–induced renal dysfunction after coronary
rocedures carries poor prognosis (4,5), especially if
See page 1035
dialysis becomes necessary (5). In addition, coro-
nary revascularization procedures in patients with
renal impairment are associated with markedly higher
risks of both fatal and nonfatal adverse outcomes (6,7).
Consequently, careful selection of high-risk patients for
referral to coronary angiography and revascu-
larization is of paramount importance.
Unfortunately, traditional approaches
for cardiac risk assessment, including
stress imaging, have been unable to accu-
rately identify low-risk individuals in this
patient subgroup (8). This may be related,
in part, to the fact that noninvasive imag-
ing methods are insensitive for detecting
the presence of diffuse atherosclerosis and
its impact on coronary epicardial and micro-
circulatory function and myocardial ischemia.
The latter may help explain the increase in
biomarkers of myocardial injury including se-
rum N-terminal pro B-type natriuretic peptide and
roponin T seen among patients with renal dysfunc-
ion and their effects on prognosis (9). This issue is of
relevance because both microvascular dysfunction and
myocardial ischemia may be amenable to treatment.
This study was designed to test the hypothesis
that in patients with moderate to severe renal
dysfunction, coronary vasodilator dysfunction, as
measured by positron emission tomography (PET),
is prevalent and helps explain the observed excess
risk of cardiac mortality in this population.
M E T H O D S
Study population. All patients with moderate to
evere renal dysfunction (estimated glomerular fil-
ration rate [eGFR] 60 ml/min/1.73 m2) referred
or rest/stress cardiac PET at the Brigham and
se
ion
women’s Hospital (Boston, Massachusetts) be-ween January 1, 2006, and June 30, 2010, were
ncluded in this study, excluding those whose im-
ges were missing or uninterpretable due to poor
mage quality. In cases of repeat PET scans during
he study period, only the earliest evaluable study
as included. Demographic factors and key ele-
ents of the patients’ history including risk factors
nd medication use were ascertained at the time of
he study by patient interview and review of medical
ecords. eGFR was calculated using the Modifica-
ion of Diet in Renal Disease formula (10) based on
mean creatinine in the 90 days preceding the
maging study. Patients being treated with chronic
enal replacement therapy, determined by patient
nterview and billing codes (11), were assumed to
ave eGFR of 1 ml/min/1.73 m2. The study was
pproved by the Partners Healthcare Institutional
eview Board and conducted in accordance with
nstitutional guidelines.
PET imaging. Patients were studied using a whole
body PET-computed tomography scanner (Discov-
ery RX or STE LightSpeed 64, GE Healthcare,
Milwaukee, Wisconsin) after an overnight fast.
Patients refrained from caffeine and methylxanthine
containing substances and drugs for 24 h prior to
their scans. Myocardial blood flow (MBF) was
measured during rest and peak stress using
rubidium-82 as a perfusion tracer, as described
previously (12). Briefly, after transmission imaging
and beginning with the intravenous bolus adminis-
tration of rubidium-82 (1,480 to 2,200 MBq), list
mode images were acquired for 7 min. Then, a
standard intravenous infusion of dipyridamole,
adenosine, regadenoson, or dobutamine was given.
At peak stress, a second dose of rubidium-82 was
injected and images were recorded in the same
manner. The average radiation exposure per study
was 4.6 mSv (13). Heart rate, blood pressure, and
12-lead electrocardiogram were recorded at baseline
and every minute during and after pharmacological
stress.
Rubidium-82 undergoes very rapid radioactive decay,
with a physical half-life of 75 s, producing trace quantities
of stable, nonradioactive krypton-82 gas, which is pas-
sively exhaled by the lungs. Neither renal nor hepatic
excretion contributes meaningfully to rubidium-82
elimination. As a result, administered tracer doses and
analytic methods do not require adjustment for renal
function.
Image analysis. SEMIQUANTITATIVE ANALYSIS OF
MYOCARDIAL PERFUSION. Semiquantitative 17-A B B R E V I A T I O N S
A N D A C R O N YM S
CAD coronary artery disea
CFR coronary flow reserve
CI confidence interval
LVEF left ventricular eject
fraction
MBFmyocardial blood flo
NRI net reclassification
improvement
PET positron emissionsegment visual interpretation of the gated myocar-
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1027dial perfusion images was performed by experienced
observers using a standard 5-point scoring system
(14). Summed rest and stress scores were calculated
as the sum of individual segmental scores on the
respective images, and their difference was recorded
as summed difference score. These were converted
to percentages of left ventricular myocardium by
dividing by the maximum score (i.e., 68).
Left ventricular systolic function. Rest and stress left
entricular ejection fraction (LVEF) were calcu-
ated from gated myocardial perfusion images using
ommercially available software. LVEF reserve was
onsidered present when LVEF increased from rest
o stress.
Quantitative MBF and ﬂow reserve. Absolute MBF
in ml/g/min) was computed from the dynamic rest
nd stress images using commercially available soft-
are (Corridor4DM, INVIA Medical Imaging So-
utions, Ann Arbor, Michigan) and previously val-
dated methods (15). Automated factor analysis was
sed to generate blood pool (arterial input function)
nd tissue time-activity curves. Regional and global rest
nd peak stress MBF were calculated by fitting the
ubidium-82 time-activity curves to a 2-compartment
racer kinetic model as described previously (15). Per-
atient global coronary flow reserve (CFR) was calcu-
ated as the ratio of absolute MBF at stress over rest for
he entire left ventricle. Quantitation of MBF was
erformed by 4 operators. The intraclass correlation
oefficient (16) for CFR among these 4 readers was 0.94
95% confidence interval [CI]: 0.88 to 0.98), indicating
xcellent reproducibility.
Assessment of outcomes. The primary outcome was
death from any cardiac cause. Patients who died
from noncardiac causes were censored. Mortality
from any cause was used as a secondary endpoint.
Vital status of all patients was ascertained by inte-
grating data from the Social Security Death Index,
the National Death Index, and the Partners
Healthcare Research Patient Data Registry. Cause
of death was determined by blinded adjudication of
hospital records and death certificates. Early revas-
cularization (within 90 days) was ascertained from
the Partners Healthcare Research Patient Data
Registry and hospital records.
Statistical analysis. Statistical significance was as-
essed using Wilcoxon, Fisher exact, and chi-square
ests for continuous, dichotomous, and categorical
ariables, respectively. Two-sided p values 0.05
ere considered significant. All statistical analyses
ere performed using SAS (version 9.3, SAS Insti-ute Inc., Cary, North Carolina).Multivariable modeling. The Cox proportional haz-
ards model was used to assess the impact of CFR on
cardiac mortality after controlling for the effects of
critical covariates. A series of models were developed
starting with the Duke Clinical Score, an index of
coronary artery disease (CAD) likelihood and prog-
nosis based on clinical covariates (17). Rest LVEF,
combined extent and severity of scar and ischemia,
stress-induced LVEF augmentation (LVEF reserve),
and CFR (as a continuous variable or dichotomized at
the median) were then sequentially incorporated into
the model. To investigate the effects of absolute peak
stress MBF, we generated an additional model con-
taining absolute stress MBF instead of CFR. The
models were examined for the validity of the propor-
tional hazards assumption and additive value, taking
care to avoid overfitting. Survival was plotted using
direct adjusted survival probabilities (18) from the Cox
survival model.
To assess for biases introduced by early revascu-
larization, analyses were repeated censoring all pa-
tients who underwent early revascularization (19).
In an exploratory analysis, we considered the effect
of any revascularization, including those 90 days
after the PET scan, as a time-dependent covariate.
Assessment of incremental value. Incremental prog-
ostic value of CFR was assessed with the likeli-
ood ratio test to determine the improvement in
rediction power of each sequential Cox model.
he C-index was calculated for each model (20)
ith comparisons using the method of Antolini et
l. (21). The potential impact of CFR on risk
tratification was assessed by net reclassification
mprovement (NRI) (22) at 2 years using threshold
nnual rates of cardiac mortality of 2% and 4%.
hese thresholds were selected to be slightly higher
han American College of Cardiology/American
eart Association guidelines for management of
hronic stable angina (23) because of the higher
eriprocedural morbidity and mortality of coronary
ngiography and revascularization in patients with
oderate to severe renal impairment (3–7). Reclas-
ification metrics using guideline-derived (23) 1%
nd 3% thresholds were also computed as a second-
ry analysis.
R E S U L T S
Patient characteristics. A total of 866 consecutive
patients met inclusion and exclusion criteria during
the study period and were followed for a median of
1.28 years (interquartile range: 0.64 to 2.34 years).
Baseline characteristics are given in Table 1. The
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1028Table 1. Patient Characteristics
No Cardiac Death
(n  778)
Cardiac Death
(n  88)
All Patients
(N  866) p Value
Demographics
Age, yrs 60.7 [51.8–70.5] 76 [65.8–82.1] 71.1 [61.3–79.8] 0.004
Male 380 (48.8) 55 (62.5) 435 (50.2) 0.02
Hispanic 76 (9.8) 3 (3.4) 79 (9.1) 0.05
Race 0.19
White 478 (61.4) 63 (71.6) 541 (62.5)
Black 138 (17.7) 11 (12.5) 149 (17.2)
Other/unknown 162 (20.8) 14 (15.9) 176 (20.3)
Risk factors
BMI, kg/m2 28.4 [24.5–33.3] 26.4 [23.1–30.3] 28.2 [24.4–33.0] 0.003
BMI 30 kg/m2 324 (41.6) 23 (26.1) 347 (40.1) 0.01
Hypertension 714 (91.8) 76 (86.4) 790 (91.2) 0.11
Dyslipidemia 540 (69.4) 66 (75.0) 606 (70.0) 0.33
Diabetes 338 (43.4) 50 (56.8) 388 (44.8) 0.02
Family history of CAD 166 (21.3) 23 (26.1) 189 (21.8) 0.34
Tobacco use 66 (8.5) 9 (10.2) 75 (8.7) 0.55
Duke clinical risk, % 56.6 [26.8–86.8] 80 [55.1–95.6] 60.5 [28–87.8] 0.0001
Renal function 0.11
CKD stage 3 508 (65.3) 51 (58.0) 559 (64.6)
CKD stage 4 89 (11.4) 17 (19.3) 106 (12.2)
CKD stage 5 181 (23.3) 20 (22.7) 201 (23.2)
Dialysis 138 (17.7) 15 (17) 153 (17.7) 1.00
eGFR MDRD, ml/min/1.73 m2 41.9 [16.6–52.1] 33.5 [19.7–44.7] 40.7 [17.3–51.8] 0.03
Medications
Aspirin 491 (63.1) 62 (70.5) 553 (63.9) 0.20
Beta-adrenergic blockers 573 (73.7) 70 (79.5) 643 (74.2) 0.25
Cholesterol agents 546 (70.2) 63 (71.6) 609 (70.3) 0.90
Insulin 167 (21.5) 27 (30.7) 194 (22.4) 0.06
Oral hypoglycemic agents 67 (8.6) 6 (6.8) 73 (8.4) 0.69
Calcium-channel blockers 253 (32.5) 16 (18.2) 269 (31.1) 0.01
ACE inhibitors 320 (41.1) 41 (46.6) 361 (41.7) 0.36
Nitrates 121 (15.6) 23 (26.1) 144 (16.6) 0.02
Diuretics 366 (47.0) 53 (60.2) 419 (48.4) 0.02
Indications
Chest pain 274 (35.2) 20 (22.7) 294 (33.9) 0.02
Dyspnea 242 (31.1) 41 (46.6) 283 (32.7) 0.01
Post-MI 112 (14.4) 19 (21.6) 131 (15.1) 0.08
Pre-operative 113 (14.5) 16 (18.2) 129 (14.9) 0.35
Cardiovascular history
Any prior CAD 405 (52.1) 70 (79.5) 475 (54.8) 0.0001
Recent MI (30 days) 137 (17.6) 27 (30.7) 164 (18.9) 0.01
Remote MI (30 days) 163 (21.0) 33 (37.5) 196 (22.6) 0.001
Prior PCI 183 (23.5) 32 (36.4) 215 (24.8) 0.01
Prior CABG 125 (16.1) 35 (39.8) 160 (18.5) 0.0001
Cerebrovascular disease 64 (8.2) 5 (5.7) 69 (8.0) 0.53
Peripheral vascular disease 60 (7.7) 19 (21.6) 79 (9.1) 0.00
Early revascularization (90 days post-PET) 76 (9.8) 12 (13.6) 88 (10.2) 0.26
Imaging parameters
Rest LVEF 55 [44–63] 35 [26–54] 54 [41–63] 0.0001
LVEF reserve 569 (73.1) 57 (64.8) 626 (72.3) 0.10
Ischemia  scar, % 2.9 [0–14.7] 16.9 [5.1–33.8] 4.4 [0–16.2] 0.0001
Ischemia, % 0 [0–5.9] 4.4 [0–8.8] 0 [0–7.4] 0.0004
Global CFR 1.53 [1.19–1.96] 1.30 [1.08–1.5] 1.49 [1.18–1.92] 0.0001
Stress global MBF, ml/g/min 1.60 [1.11–2.23] 1.21 [0.93–1.77] 1.55 [1.08–2.18] 0.0001
Rest global MBF, ml/g/min 0.99 [0.79–1.32] 1.03 [0.77–1.29] 1.00 [0.79–1.32] 0.51
CFR 1.5 405 (52.1) 22 (25.0) 427 (49.3) 0.0001
Continuous variables are presented as median (interquartile range). Dichotomous variables are presented as n (%). Patients whose LVEF
at stress was greater than that at rest were considered to have positive stress-induced increase in LVEF.
ACE  angiotensin converting enzyme; BMI  body mass index; CABG  coronary artery bypass graft; CAD  coronary artery disease;
CFR  coronary ﬂow reserve; CKD  chronic kidney disease; eGFR  estimated glomerular ﬁltration rate; LVEF  left ventricular ejection
fraction; MBF  myocardial blood ﬂow; MDRD  Modiﬁcation of Diet in Renal Disease formula; MI  myocardial infarction; PCI 
percutaneous coronary intervention; PET  positron emission tomography.
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1029most common indications for testing were evalua-
tion for chest pain, dyspnea, or their combination.
Approximately one-half of all studies were normal
by semiquantitative visual analysis.
Patient outcomes. Mortality from any cause oc-
curred in 155 (17.9%) patients, of which 88
(56.8%) were due to cardiac causes (Table 2,
Online Appendix). Three-year cardiac mortality
was 16.2%. Compared with patients without car-
diac death, those who experienced cardiac death
were older, more likely to be men, have diabetes,
had a lower body mass index, more likely to be
referred for dyspnea evaluation, have prior CAD,
lower rest LVEF, and larger abnormalities on PET
scans (Table 1).
The annualized rate of cardiac death increased
with increasing extent and severity of perfusion
abnormalities (Fig. 1A) and, importantly, was 2.7%
per year among patients with a visually normal PET
scan. Furthermore, in each category of abnormality
on PET scanning (combined ischemia and scar
extent), an impaired CFR identified higher risk
subgroups, including among those with visually
normal scans (Fig. 1B). Likewise, in each category
of LVEF, a higher CFR was associated with a
decrease in the risk of cardiac mortality (Fig. 1C).
Univariate predictors of cardiac mortality. CFR values
below the median were associated with a 3.3-fold
increased risk of cardiac death. Other significant
predictors of increased risk included age, male sex, dia-
betes, and prior CAD (Fig. 2, Online Appendix).
Somewhat surprisingly, chest pain as a reason for
testing was associated with a decreased risk, possi-
bly reflecting confounding. In addition, dyspnea, a
decrease in rest LVEF, as well as increasing burden
of scar, ischemia, or their combination on semi-
quantitative visual analysis, were all significantly
associated with increased risk.
Multivariable survival analysis and incremental
prognostic value. A series of multivariable models
were then constructed to assess the incremental
value of CFR after adjustment for critical covariates
known to be associated with increased risk of
cardiac mortality (Table 2). Addition of CFR to a
model including the Duke clinical risk score, early
revascularization, eGFR, rest LVEF, LVEF re-
serve, and the total burden of ischemia and scar was
associated with a significant increase in global
chi-square and decrease in Akaike Information
Criterion, indicating improved model fit, improved
model calibration, and a borderline significant in-
crease in the C-index from 0.75 to 0.77 (p  0.05).ichotomization of CFR at the median value led toT G A C C C D E e R Is L C V to
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1030better model fit than as a continuous variable. Com-
pared with those with CFR 1.5, the fully adjusted
azard ratio for cardiac death was 2.1 (95% CI: 1.3 to
.5, p  0.0004) for those with CFR 1.5 (Fig. 2).
Risk reclassiﬁcation. Addition of CFR estimates to
the model resulted in the reclassification of 14%, 36%,
and 12% of patients at low (2% annualized cardiac
mortality), intermediate (2% to 4% annualized cardiac
mortality), and high cardiac risk (4% annualized
cardiac mortality), respectively, based on the pre-CFR
model (Table 2, Model 5; Fig. 3). The benefit of CFR
on risk reclassification was greatest among patients
with an intermediate pre-CFR risk, in whom addition
of CFR to risk estimation downgraded risk in 21%
(0% annualized cardiac mortality) and upgraded it in
15% (9.8% annualized cardiac mortality).
In the entire cohort, 19.5% of patients were
reclassified (7.7% upward and 11.8% downward)
into more accurate risk categories. NRI was 0.142
(95% CI: 0.076 to 0.219) across clinical risk cate-
gories of2, 2 to 4, and4% annual rate of cardiac
death (Table 2, Online Appendix). The effect of
reclassification was most pronounced among those
patients classified as low (NRI  0.914, 95% CI:
.817 to 1.11) or intermediate risk without CFR
NRI  0.489, 95% CI: 0.192 to 0.836). However,
significant reclassification was also seen among
patients classified as high risk without CFR (NRI 
0.145, 95% CI: 0.106 to 0.185). Using thresholds
of 1, 1 to 3, and 3% annual rate of cardiac death,
he NRI for all patients was 0.098 (95% CI: 0.055 to
.148). The continuous NRI, which measures dis-
riminatory potential, was 0.390 (95% CI: 0.131 to
.639).
All-cause mortality. Analyses were repeated using
ortality from any cause as a secondary outcome
nd the results were similar. After correction for
linical risk, left ventricular systolic function, extent
f ischemia and scar, and stress-induced LVEF
ugmentation, CFR remained a significant predic-
or of mortality with CFR 1.5 associated with a
azard ratio of 1.9 (95% CI: 1.3 to 2.8, p 
.0004). Addition of CFR was associated with
avorable risk reclassification for all-cause mortality
continuous NRI  0.461; 95% CI: 0.257 to
.658). Using risk thresholds of 4% and 8% per year
double those for cardiac mortality), the NRI was
.129 (95% CI: 0.044 to 0.222).
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Figure 1. Unadjusted Cardiac Mortality
Unadjusted annualized cardiac mortality in categories of total extent of
myocardial ischemia and scar (A); and by coronary ﬂow reserve (CFR) above
and below median (1.5) and categories of total extent of myocardial ische-
mia and scar (B); and by CFR above and below median and categories of
left ventricular ejection fraction (LVEF) (C). The annual rate of cardiac death
increased with increasing extent of ischemia and scar, decreasing LVEF and
CFR. Importantly, lower CFR consistently identiﬁed higher risk patients at
every level of ischemia and scar extent and LVEF, including among those
with visually normal positron emission tomography scans and normal leftseverity of coronary vascular dysfunction, as as-
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1031sessed by PET, is an independent predictor of
cardiac death in patients with moderate or severe
renal impairment. We observed that the failure of
MBF to increase adequately on demand identified
patients with renal impairment who experienced a
significantly higher rate of cardiac mortality (10.7%
vs. 3.2% per year in those with relatively preserved
coronary vasodilator reserve, p  0.0001). Impor-
antly, identification of coronary vasodilator dys-
unction improved risk stratification beyond com-
rehensive clinical assessment, left ventricular
ystolic function, and semiquantitative measures of
yocardial ischemia and scar. Indeed, a quantitative
stimate of coronary vasodilator reserve in this
ohort was able to improve risk stratification in
ore than one-third of patients with intermediate
isk, appropriately downgrading risk in 15% and
pgrading it in 21% of patients.
Prior studies have shown that coronary vasodilator
unction assessment improves prognostic assessment
24). This study demonstrates the benefits of improved
isk stratification by quantitative measures of coronary
ascular dysfunction also apply to patients with moderate
o severe renal dysfunction, who are among the highest
isk cohorts for CAD complications. Although future
tudies will be required to determine how CFR metrics
hould best be incorporated into treatment strategies,
ore aggressive medical treatment of patients with visu-
lly normal perfusion but impaired flow reserve could
otentially improve outcomes. Similarly, it is possible
hat avoidance of angiography and revascularization in
ersons with myocardial scar and/or ischemia but with
reserved CFR may decrease nephrotoxicity without
ompromising safety.
Noninvasive measures of coronary vasodilator
eserve integrate the hemodynamic effects of focal
picardial coronary stenoses, the fluid dynamic ef-
ects of diffuse atherosclerosis, and the presence of
oronary microvascular dysfunction. Thus, the close
elationship between the blunting of the increase in
BF with stress and prognosis could be due to any
r all of these. Patients with renal impairment may
e more likely to have advanced multivessel epicar-
ial coronary disease (25) and more rapid progres-
ion of disease (26), both of which may contribute
o adverse prognosis (27). Prior investigations have
lso suggested that renal disease is associated with
bnormal coronary vasodilator function (28), which
ay result from multiple mechanisms (29), includ-
ng decreased capillary density (30) leading to mi-
rovascular dysfunction as well as vascular remod-
ling in epicardial arteries (31). Our demonstration
f increased cardiac mortality in patients whofailed to augment MBF in response to stress in
the absence of overt evidence of myocardial
ischemia (5.9% vs. 1.1% per year for those with
relatively preserved flow reserve, p  0.002)
provides new evidence that microvascular abnor-
malities play a role in the increased cardiovascular
risk of patients with renal impairment. This is
supported by prior studies showing that angio-
graphic measures of coronary disease severity
could not fully explain the increased risk observed
in patients with renal dysfunction (32). Conse-
quently, it is likely that either diffuse atheroscle-
rosis or microvascular dysfunction or both to-
gether account for at least part of the increased
risk observed in patients with poor coronary
Log-Rank P< 0.0001
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Figure 2. Cardiac Mortality
Incidence of cardiac mortality for patients’ CFR above and below th
median (1.5) presented in Kaplan-Meier form (A) showing signiﬁcan
increased risk of cardiac mortality with CFR 1.5 (p  0.0001), whi
tinued after adjustment (18) for clinical risk (Duke clinical score [17
revascularization, rest LVEF, extent of myocardial ischemia and scar
LVEF reserve (B) (p  0.0004). Graphs are censored at 3 years for si
HR  hazard ratio; other abbreviations as in Figure 1.3
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1032Study limitations. The current study is a single-
enter, nonrandomized, observational study and
arries all of the inherent limitations of that study
esign. As such, it is likely that some amount of
esidual confounding remains, despite careful ad-
ustment for clinically relevant covariates. On the
ther hand, compared with data derived from pa-
ients selectively enrolled in a randomized trial,
hese data, with very limited exclusion criteria, may
e more representative of patients seen in routine
linical practice. Although the Modification of Diet
n Renal Disease formula for eGFR has been
xtensively validated, it represents an estimate of
enal function at a single time point. However, for
9% of patients in this study, 2 creatinine values
ere averaged, reducing the impact of fluctuations.
At present, cardiac PET is only available at a
elatively small number of institutions compared
ith other stress testing modalities such as single-
hoton emission computed tomography and echo-
ardiography. However, with increased PET scan-
er availability and emerging longer half-life tracers
or myocardial perfusion imaging available for unit
ose distribution (33), accessibility of cardiac PET
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Figure 3. Risk Reclassiﬁcation
Illustration of risk reclassiﬁcation by addition of CFR to a model con
of myocardial ischemia and scar. The height of each bar is proporti
2 to 4, and 4% per year risk of cardiac death) as estimated by a m
extent of myocardial ischemia and scar (Model 4, Table 2). Each of
reclassiﬁed as 2 (green), 2 to 4 (blue), and 4% (red) per year ris
model (Model 5, Table 2). The horizontal bar charts at right represe
post-CFR risk categories. Abbreviations as in Figure 1.s likely to continue to improve (34).Other methods of stress imaging are not able to
outinely quantify myocardial perfusion. Advances
n single-photon emission computed tomography
maging technology might enable this in the near
uture. Routine stress echocardiography can detect
mpaired myocardial perfusion once severe enough
o result in overt systolic dysfunction, quantification
f subclinical abnormalities in myocardial perfusion
equires more advanced methods than are available
t most sites. One approach, Doppler interrogation
f coronary flow velocities, typically in the left
nterior descending artery, has been demonstrated
o identify patients at risk of future coronary events
35). This method requires excellent acoustic win-
ows, which are often not available due to body
abitus or lung disease. Furthermore, this technique
an only evaluate a subset of the coronary tree and
ay thus underestimate disease burden. Myocardial
ontrast echocardiography may increase the propor-
ion of evaluable myocardium, but lacks regulatory
pproval in the United States.
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1033vasodilator function provides incremental risk stratifi-
cation beyond routine measures of clinical risk, includ-
ing estimates of left ventricular systolic function and
the extent and severity of myocardial ischemia and
scar, and results in a meaningful risk reclassification of
1 in 5 patients with known or suspected CAD. These
findings have potentially important implications for
optimal identification of high-risk individuals andCardiovasc Imaging 2009;2:429–36.
1
1
1
1
1
1
1
ity. Psychol Bull 19especially given the markedly higher rates of morbidity
and mortality associated with cardiac catheterization
and revascularization in patients with renal impair-
ment (6,7).
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